Literature DB >> 1311983

Prognostic factors in 227 patients with malignant fibrous histiocytoma.

C M Pezzi1, M S Rawlings, J J Esgro, R E Pollock, M M Romsdahl.   

Abstract

Malignant fibrous histiocytoma, the major subset of soft tissue sarcomas, was examined for prognostic factors that could influence clinical management and research. Two hundred twenty-seven patients with localized disease, having surgery as the principal modality, were reviewed retrospectively to identify clinical outcomes. The mean age of the patients was 54 years. Extremities were the primary tumor site in 157 patients (62.2%). Overall survival rate was 50%, including 38 patients who died of other causes. Distant metastases were most common to the lung (90%). Local recurrence alone occurred in 37 patients (16%), distant metastases alone in 52 (23%), and distant metastases with local recurrence in 25 (11%). The primary tumor size indicated the 5-year survival rate: tumors smaller than 5 cm had a survival rate of 82%; 5 to 10 cm, 68%; and larger than 10 cm, 51%. Intermediate-grade tumors yielded a 5-year survival rate of 80%, and the 5-year survival rate for high-grade tumors was 60%. Survival rates for both grades were affected by size: tumors of high grade and smaller than 5 cm in diameter had a survival rate of 79%; 5 to 10 cm, 63%; and more than 10 cm, 41%. Grade and size emerge as significant prognostic indicators. These variables will prove helpful in treatment decisions and design of clinical studies.

Entities:  

Mesh:

Year:  1992        PMID: 1311983     DOI: 10.1002/1097-0142(19920415)69:8<2098::aid-cncr2820690815>3.0.co;2-9

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  31 in total

1.  Retroperitoneal malignant fibrous histiocytoma.

Authors:  D Répássy; S Csata; G Sterlik; P Hazslinszky
Journal:  Int Urol Nephrol       Date:  1999       Impact factor: 2.370

Review 2.  Malignant fibrous histiocytoma: past, present, and future.

Authors:  A E Rosenberg
Journal:  Skeletal Radiol       Date:  2003-09-27       Impact factor: 2.199

3.  Comparative genomic hybridization of malignant fibrous histiocytoma reveals a novel prognostic marker.

Authors:  M L Larramendy; M Tarkkanen; C Blomqvist; M Virolainen; T Wiklund; S Asko-Seljavaara; I Elomaa; S Knuutila
Journal:  Am J Pathol       Date:  1997-10       Impact factor: 4.307

4.  Malignant fibrous histiocytoma originating from the mesorectum: a case report.

Authors:  Yoshifumi Nakayama; Noritaka Minagawa; Takayuki Torigoe; Koji Yamaguchi
Journal:  World J Surg Oncol       Date:  2011-02-02       Impact factor: 2.754

5.  Undifferentiated Pleomorphic Sarcoma after Pirfenidone Use: A Case Report.

Authors:  Christine A Moore; Aaysha Kapila
Journal:  Perm J       Date:  2018

6.  Serial growth of human malignant fibrous histiocytoma xenografts in immunodeficient mice.

Authors:  N Kurihara; T Kubota; Y Otani; M Watanabe; K Kumai; M Kitajima
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

7.  Expression of matrix metalloproteinase-9 correlates with poor prognosis in human malignant fibrous histiocytoma.

Authors:  Jinyoung Yoo; Ji Han Jung; Seok Jin Kang; Chang Suk Kang
Journal:  Cancer Res Treat       Date:  2004-12-31       Impact factor: 4.679

8.  Multiple (five) synchronous primary malignant neoplasms of dissimilar histogenesis including a malignant fibrous histiocytoma of the bladder.

Authors:  K Weingärtner; M D Melekos; E W Gerharz; U Köhl; K Neumann; H Riedmiller
Journal:  Int Urol Nephrol       Date:  1995       Impact factor: 2.370

9.  A case of intermittent lumbar pain radiating to the right shoulder in a 76-year-old woman.

Authors:  Luciano Cardinale; Francesco Ardissone; Ubaldo Familiari; Mariaelena Perna; Cesare Fava
Journal:  Eur Radiol       Date:  2009-07-22       Impact factor: 5.315

10.  [Locally recurrent malignant fibrous histiocytoma of the kidney and spermatic cord].

Authors:  M May; F Marusch; C Helke; S Gunia; I Gastinger; B Hoschke
Journal:  Urologe A       Date:  2004-08       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.